Login to Your Account



Hemophilia heats up: Baxter snags Chatham Therapeutics for $70M

By Marie Powers
Staff Writer

Wednesday, April 2, 2014
Days after the FDA approved Biogen Idec Inc.’s Alprolix (coagulation factor IX [recombinant], Fc fusion protein) as the first recombinant, DNA-derived hemophilia B therapy with prolonged circulation, Baxter International Inc. moved to strengthen its own hemophilia franchise by snapping up the assets of Chatham Therapeutics LLC in a $70 million deal plus potential development, regulatory and commercial milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription